Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China flag China · Delayed Price · Currency is CNY
5.12
-0.07 (-1.35%)
Nov 18, 2026, 3:00 PM CST

SHA:600713 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
55,36254,81053,56853,47350,07444,964
Other Revenue
153.12153.12128.05116.29147.48159.08
55,51554,96353,69653,59050,22245,123
Revenue Growth
3.01%2.36%0.20%6.71%11.30%13.33%
Cost of Revenue
52,04251,59750,34150,28346,96942,190
Gross Profit
3,4733,3663,3553,3073,2522,934
Selling, General & Admin
1,7631,7131,6661,6911,6451,509
Research & Development
51.4146.7930.6436.1927.4320.96
Other Operating Expenses
104.47116.3494.3196.35116.5591.37
Operating Expenses
2,0562,0181,8181,8071,8641,633
Operating Income
1,4181,3491,5371,5001,3891,301
Interest Expense
-306.27-309.01-325.82-522.23-332.9-439
Interest & Investment Income
26.2325.4317.6218.7211.4113.17
Other Non Operating Income (Expenses)
-220.32-217.58-218.47-19.42-136.95-17.44
EBT Excluding Unusual Items
917.31847.441,011977.09930.24857.44
Impairment of Goodwill
-8.92-8.92----
Gain (Loss) on Sale of Investments
-0.240.28---48.64-87.74
Gain (Loss) on Sale of Assets
286.15293.313.771.7523.7960.54
Asset Writedown
-0.83-----
Other Unusual Items
15.8325.51-10.94-0.770.638.63
Pretax Income
1,2091,1581,003978.07906.01838.87
Income Tax Expense
361.55324.96260.28265.26190.09228.31
Earnings From Continuing Operations
847.75832.67743.12712.81715.92610.55
Minority Interest in Earnings
-209.67-207.83-172.49-134.98-120.25-105.37
Net Income
638.08624.83570.63577.83595.67505.18
Net Income to Common
638.08624.83570.63577.83595.67505.18
Net Income Growth
20.23%9.50%-1.25%-3.00%17.91%34.21%
Shares Outstanding (Basic)
1,2991,3021,3031,2981,2541,042
Shares Outstanding (Diluted)
1,4751,4671,3031,2981,2541,042
Shares Change
4.13%12.58%0.33%3.54%20.39%-0.10%
EPS (Basic)
0.490.480.440.450.470.48
EPS (Diluted)
0.430.430.440.450.470.48
EPS Growth
15.46%-2.74%-1.57%-6.32%-2.06%34.35%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,709-159.571,5911,748-837.59388.79
Free Cash Flow Per Share
-1.16-0.111.221.35-0.670.37
Dividend Per Share
0.2600.1700.1700.1600.1400.120
Dividend Growth
52.94%0%6.25%14.29%16.67%9.09%
Gross Margin
6.26%6.12%6.25%6.17%6.48%6.50%
Operating Margin
2.55%2.45%2.86%2.80%2.77%2.88%
Profit Margin
1.15%1.14%1.06%1.08%1.19%1.12%
Free Cash Flow Margin
-3.08%-0.29%2.96%3.26%-1.67%0.86%
EBITDA
1,5581,4951,6911,6541,5431,448
EBITDA Margin
2.81%2.72%3.15%3.09%3.07%3.21%
D&A For EBITDA
140.24146.15154.02153.76153.84147.27
EBIT
1,4181,3491,5371,5001,3891,301
EBIT Margin
2.55%2.45%2.86%2.80%2.77%2.88%
Effective Tax Rate
29.90%28.07%25.94%27.12%20.98%27.22%
Revenue as Reported
55,51554,96353,69653,59050,22245,123